Does Hormonal Luteal Support After Intra-uterine Insemination (IUI) Increase the Pregnancy Rate?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00700492
Recruitment Status : Terminated (Change in Belgian law on the use of hMG in IUI)
First Posted : June 18, 2008
Last Update Posted : June 25, 2015
Information provided by (Responsible Party):
Thomas D'Hooghe, University Hospital, Gasthuisberg

Brief Summary:
A randomized study to investigate if hormonal luteal support after intra-uterine insemination (IUI) in ovulation induction cycles with human menopausal gonadotropin increases the pregnancy rate

Condition or disease Intervention/treatment
Subfertility Drug: progesterone

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Luteal Support With Vaginal Progesterone Capsules Following Ovulation Induction With Human Menopausal Gonadotropins (hMG) for Intra Uterine Insemination: A Comparative Study
Study Start Date : May 2004
Primary Completion Date : March 2008
Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
No Intervention: control
Experimental: utrogestan
daily use of vaginal progesterone capsules
Drug: progesterone
vaginal capsules 3X200mg daily
Other Name: Utrogestan

Primary Outcome Measures :
  1. clinical pregnancy rate per cycle [ Time Frame: 12 weeks pregnancy ]

Secondary Outcome Measures :
  1. rate of miscarriages per cycle [ Time Frame: 12 weeks pregnancy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 43 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Signed informed consent
  • Tubal patency demonstrated
  • ovulation induction with human menopausal gonadotropin

Exclusion Criteria:

  • ovulation induction with clomiphene citrate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00700492

Leuven University Fertility Center
Leuven, Vlaams Brabant, Belgium, 3000
Sponsors and Collaborators
University Hospital, Gasthuisberg
Principal Investigator: Thomad D'Hooghe, MD, PhD University Hospital Gasthuisberg, Catholic University Leuven, Belgium

Responsible Party: Thomas D'Hooghe, Prof PhD MD, University Hospital, Gasthuisberg Identifier: NCT00700492     History of Changes
Other Study ID Numbers: ML2437-30/12/2003
First Posted: June 18, 2008    Key Record Dates
Last Update Posted: June 25, 2015
Last Verified: June 2015

Keywords provided by Thomas D'Hooghe, University Hospital, Gasthuisberg:
pregnancy rate

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents